Here, I will let you in on some interesting DD. Did you all know that a little known Canadian company Akela Pharma is the manufacturer of this product? Their Pharmaform division does $14 million / year in revs, has no debt and is marginally profitable. A market cap of under $5 million with low float. They just did a financing to buy new production equipment. The CEO and Ingalls and Snyder are the major financiers. Horace Boone is an exec at Ingalls and Snyder. The same Ingalls and Snyder that is a major holder of CORT. Ticker is AKL on the TSX exchange, check it out;
Took a closer look at AKL and they do have debt on their books (I thought they were debt free other than recent debenture financing)and they have a large account payable and a bit of a shaky balance sheet so do your DD before making any purchase. They just released year end, available on www.sedar.ca I would suggest you read and buy at your own risk.